Features of the course of cardiovascular pathology and type 2 diabetes mellitus in patients with COVID-19

DOI: https://doi.org/10.29296/25877305-2021-01-01
Download full text PDF
Issue: 
1
Year: 
2021

Professor E. Polozova(1)*, MD; V. Skvortsov(2), MD; L. Chegodaeva(1), Candidate of Medical
Sciences; N. Kurkina(1)**, Candidate of Medical Sciences; T. Prokhorova(1); N.B.A. Al-Zakhar(1); N.
Nefedov(1)*** (1)National Research Ogarev Mordovia State University, Saransk, Russia (2)Volgograd State
Medical University, Volgograd, Russia

Acute respiratory viral diseases, including coronavirus disease, cause the progression of pre-existing chronic non-infectious diseases, including cardiovascular diseases (CVD) and type 2 diabetes mellitus (DM). The emergence of life-threatening complications against the background of a new coronavirus infection makes it necessary to study the features of the course of cardiovascular pathology and type 2 diabetes mellitus in conditions of this pathology. The regularities of the course of CVD and DM, as well as the development of complications in patients with COVID-19, are currently not completely established. The article provides an overview of the literature on the features of the course of cardiovascular pathology and type 2 diabetes mellitus in patients with COVID-19. The issue of the possibility of using drug therapy in patients with cardiovascular diseases, type 2 diabetes mellitus and COVID-19 is being discussed.
Keywords: 
infectious diseases
coronavirus
cardiovascular disease
diabetes mellitus
COVID-19

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Belikina D.V., Malysheva E.S., Petrov A.V. i dr. COVID-19 pri soputstvujuschem saharnom diabete: osobennosti klinicheskogo techenija, metabolizma, vospalitel'nyh i koaguljatsionnyh narushenij. Sovremennye tehnologii v meditsine. 2020; 12 (5): 6–18 [Belikina D.V., Malysheva E.S., Petrov A.V. et al. COVID-19 in patients with diabetes: clinical course, metabolic status, inflammation, and coagulation disorder. Sovremennye tehnologii v medicine. 2020; 12 (5): 6–18 (in Russ.)]. https://doi.org/10.17691/stm2020.12.5.01
  2. Schiffrin E.L., Flack J.M., Ito S. et al. Hypertension and COVID-19. Am J Hypertens. 2020; 33 (5): 373–4. DOI: 10.1093/ajh/hpaa057
  3. Zhmerenetskij K.V., Vit'ko A.V., Petrichko T.A. i dr. Slozhnye voprosy vedenija patsientov s COVID-19, komorbidnyh po serdechno-sosudistym zabolevanijam i saharnomu diabetu 2-go tipa. Dal'nevostochnyj meditsinskij zhurnal. 2020; 2: 102–14 [Zhmerenetskii K.V., Vitko A.V., Petrichko T.A. et al. Difficult issues of management and treatment of patients with underlying comborid background (cardiovascular diseases, diabetes type 2). Dal’nevostochnyi meditsinskii zhurnal. 2020; 2: 102–14 (in Russ.)]. DOI: 10.35177/1994-5191-2020-2-101-113
  4. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020; 14 (3): 247–50. DOI: 10.1016/j.dsx.2020.03.013
  5. Starshinova A.A., Kushnareva E.A., Malkova A.M. i dr. Novaja koronavirusnaja infektsija: osobennosti klinicheskogo techenija, vozmozhnosti diagnostiki, lechenija i profilaktiki infektsii u vzroslyh i detej. Voprosy sovremennoj pediatrii. 2020; 19 (2): 123–31 [Starshinova A.A., Kushnareva E.A., Malkova A.M. et al. New Coronaviral Infection: Features of Clinical Course, Capabilities of Diagnostics, Treatment and Prevention in Adults and Children. Current Pediatrics. 2020; 19 (2): 123–31 (in Russ.)]. https://doi.org/10.15690/vsp.v19i2.2105
  6. Ojnotkinova O.Sh., Larina V.N., Zajrat'jants O.V. Oslozhnenija so storony serdechno-sosudistoj sistemy pri COVID-19. Moskovskaja meditsina. 2020; 3 (37): 80–9 [Oynotkinova O.Sh., Larina V.N., Zayratyants O.V. Cardiovascular complications in COVID-19. Moskovskaya meditsina. 2020; 3 (37): 80–9 (in Russ.)].
  7. Kreutz R., Algharably E.A., Azizi M. et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020; 116 (10): 1688–99. DOI: 10.1093/cvr/cvaa097
  8. Cole J.E., Park I., Ahern D.J. et al. Immune cell census in murine atherosclerosis: cytometry by time of fl ight illuminates vascular myeloid cell diversity. Cardiovasc Res. 2018; 114 (10): 1360–71. DOI: 10.1093/cvr/cvy109
  9. Matysiak-Budnik T., Heyman M., Megraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003; 18 (Suppl. 1): 55–62. DOI: 10.1046/j.1365-2036.18.s1.6.x
  10. Lin L., Jiang X., Zhang Z. at al. Gastrointestinal Symptoms of 95 Cases With SARS-CoV-2 Infection. Gut. 2020; 69 (6): 997–1001. DOI: 10.1136/gutjnl-2020-321013
  11. Shim S., Jang H.S., Myung H.W. et al. Rebamipide ameliorates radiation-induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017; 15 (329): 40–7. DOI: 10.1016/j.taap.2017.05.012
  12. Liu K., Fang Y.Y., Deng Y. et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020; 133 (9): 1025–31. DOI: 10.1097/CM9.0000000000000744
  13. Shestakova M.V., Vikulova O.K., Isakov M.A. i dr. Saharnyj diabet i COVID-19: analiz klinicheskih ishodov po dannym registra saharnogo diabeta Rossijskoj Federatsii. Problemy endokrinologii. 2020; 66 (1): 35–46 [Shestakova M.V., Vikulova O.K., Isakov M.A. et al. Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the russian diabetes registry. Problems of Endocrinology. 2020; 66 (1): 35–46 (in Russ.)]. https://doi.org/10.14341/probl12458
  14. Wang A., Zhao W., Xu Z. et al. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract. 2020; 162: 108–18. DOI: 10.1016/j.diabres.2020.108118
  15. Zhou F., Zhang Y., Chen J. et al. Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol. 2016; 791: 735–40. DOI: 10.1016/j.ejphar.2016.10.016
  16. Kohio H.P., Adamson A.L. Glycolytic control of vacuolar-type ATPase activity: a mechanism to regulate influenza viral infection. Virology. 2013; 444 (1–2): 301–9. DOI: 10.1016/j.virol.2013.06.026
  17. Gupta R., Ghosh A., Singh A.K. et al. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020; 14 (3): 211–2. DOI: 10.1016/j.dsx.2020.03.002